AI Article Synopsis
- This study examined the effectiveness and safety of macrolide antibiotics in treating children with bronchiectasis, analyzing data from seven randomized controlled trials.
- The findings showed that long-term macrolides significantly reduced the presence of Moraxella catarrhalis but had no impact on other pathogens or lung function (measured by FEV1%).
- Overall, macrolides did not lead to an increased risk of adverse events, but larger studies are needed to confirm these results.
Article Abstract
Background: This study summarized the available randomized controlled trials (RCTs) to assess the efficacy and safety of macrolides on pathogens, lung function, laboratory parameters, and safety in children with bronchiectasis.
Methods: PubMed, EMBASE, and the Cochrane Library were searched for available papers published up to June 2021. The outcomes were the pathogens, adverse events (AEs), and the forced expiratory volume in one second (FEV1%) predicted.
Results: Seven RCTs (633 participants) were included. The long-term use of macrolides reduced the risk of the presence of Moraxella catarrhalis (RR = 0.67, 95% CI: 0.30-1.50, P = 0.001; I = 0.0%, P = 0.433), but not Haemophilus influenza (RR = 0.19, 95% CI: 0.08-0.49, P = 0.333; I = 57.0%, P = 0.040), Streptococcus pneumonia (RR = 0.91, 95% CI: 0.61-1.35, P = 0.635; I = 0.0%, P = 0.515), Staphylococcus aureus (RR = 1.01, 95% CI: 0.36-2.84, P = 0.986; I = 61.9%, P = 0.033), and any pathogens present (RR = 0.61, 95% CI: 0.29-1.29, P = 0.195; I = 80.3%, P = 0.006). Long-term macrolides had no effect on FEV1% predicted (WMD = 2.61, 95% CI: -1.31, 6.53, P = 0.192; I = 0.0%, P = 0.896). Long-term macrolides did not increase the risk of AEs or serious AEs.
Conclusion: Macrolides do not significantly reduce the risk of pathogens present (except for Moraxella catarrhalis) or increase FEV1% predicted among children with bronchiectasis. Moreover, macrolides were not associated with AEs. Considering the limitations of the meta-analysis, further larger-scale RCTs are needed to confirm the findings.
Impact: Macrolides do not significantly reduce the risk of pathogens present (except for Moraxella catarrhalis) among children with bronchiectasis. Macrolides do not significantly increase FEV1% predicted among children with bronchiectasis. This meta-analysis reports on the efficacy and safety of macrolides in the treatment of children with bronchiectasis, providing evidence for the management of children with bronchiectasis. This meta-analysis does not support the use of macrolides in the management of children with bronchiectasis unless the presence of Moraxella catarrhalis is provenor suspected.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41390-023-02591-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Novel gene mutation causing primary combined immunodeficiency disease: A case report and literature review.
Cent Eur J Immunol
September 2024
This study presents a detailed clinical case of a 10-year-old boy with a history of prolonged cough, fever, and delayed diagnosis of bronchiectasis. Review of the case revealed that the child has had recurrent bronchitis, otitis media, skin allergies, and viral warts since early childhood, indicating persistent immune system abnormalities. Imaging studies, including pulmonary and sinus CT scans, show significant bronchiectasis accompanied by infections and sinusitis.
View Article and Find Full Text PDFPrimary Staphylococcal Lung Abscess: A Rare Situation in Infants.
Cureus
November 2024
Pediatric Surgery, Mohammed VI University Hospital, Oujda, MAR.
Primary pulmonary abscess is a rare but serious localized bacterial infection of the lung parenchyma, occurring without prior lung conditions like bronchiectasis or necrotizing pneumonia. We report the case of an 11-month-old child with a 22-day history of productive cough and fever, unresponsive to initial antibiotics. Clinical examination showed a stable, eupneic child with mild fever and reduced oxygen saturation.
View Article and Find Full Text PDFHealth inequalities in respiratory tract infections - beyond COVID-19.
Curr Opin Infect Dis
December 2024
Division of Medical Sciences, Northern Ontario School of Medicine University, Thunder Bay, Ontario, Canada.
Purpose Of Review: To discuss recent findings on the global burden of respiratory tract infections in underprivileged populations, highlighting the critical role of socioeconomic factors in the incidence and severity of these diseases, with a particular focus on health disparities affecting Indigenous communities.
Recent Findings: Pulmonary tuberculosis and lower respiratory tract infections, particularly those caused by Streptococcus pneumoniae and respiratory syncytial virus (RSV), continue to disproportionally impact populations in low-income countries and Indigenous communities worldwide. Indigenous children <5 years old bear the highest global burden of RSV infection, reflecting persistent social inequalities between Indigenous and non-Indigenous populations.
Etiology and clinical features of children with bronchiectasis-Insight from Chinese experience.
Pediatr Pulmonol
December 2024
Department of Respiratory, Shenzhen Children's Hospital, Shenzhen, China.
Bronchiectasis is a clinical syndrome characterized by cough, sputum production, and the presence of abnormal thickening and dilation of the bronchial wall on imaging. There has been a remarkable resurgence in incidence and prevalence during the past 20 years. There was few data from children.
View Article and Find Full Text PDFClinical and molecular profile of 20 patients with DOCK8 deficiency-a single-center experience from Southern India.
Immunol Res
December 2024
Paediatric Immunology and Rheumatology Unit, Aster CMI Hospital, Bengaluru, India.
DOCK8 deficiency is the most common cause of autosomal recessive hyper-IgE syndrome (AR-HIES). The clinical spectrum is wide resulting in combined immunodeficiency, atopy, autoimmunity, and malignancies. To study the clinical and molecular profile of 20 patients with DOCK8 deficiency.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!